

Pharmacotherapy for Mood Disorders in Pregnancy

A Review of Pharmacokinetic Changes and Clinical Recommendations for Therapeutic Drug Monitoring

Kristina M. Deligiannidis, MD,*†‡ Nancy Byatt, DO, MBA,‡§ and Marlene P. Freeman, MD||

Objective: Pharmacotherapy for mood disorders during pregnancy is often complicated by pregnancy-related pharmacokinetic changes and the need for dose adjustments. The objectives of this review are to summarize the evidence for change in perinatal pharmacokinetics of commonly used pharmacotherapies for mood disorders, discuss the implications for clinical and therapeutic drug monitoring (TDM), and make clinical recommendations.

Methods: The English-language literature indexed on MEDLINE/PubMed was searched for original observational studies (controlled and uncontrolled, prospective and retrospective), case reports, and case series that evaluated or described pharmacokinetic changes or TDM during pregnancy or the postpartum period.

Results: Pregnancy-associated changes in absorption, distribution, metabolism, and elimination may result in lowered psychotropic drug levels and possible treatment effects, particularly in late pregnancy. Mechanisms include changes in both phase 1 hepatic cytochrome P450 and phase 2 uridine diphosphate glucuronosyltransferase enzyme activities, changes in hepatic and renal blood flow, and glomerular filtration rate. Therapeutic drug monitoring, in combination with clinical monitoring, is indicated for tricyclic antidepressants and mood stabilizers during the perinatal period.

Conclusions: Substantial pharmacokinetic changes can occur during pregnancy in a number of commonly used antidepressants and mood stabilizers. Dose increases may be indicated for antidepressants including citalopram, clomipramine, imipramine, fluoxetine, fluvoxamine, nortriptyline, paroxetine, and sertraline, especially late in pregnancy. Antenatal dose increases may also be needed for lithium, lamotrigine, and valproic acid because of perinatal changes in metabolism. Close clinical monitoring of perinatal mood disorders and TDM of tricyclic antidepressants and mood stabilizers are recommended.

Key Words: pharmacokinetics, pregnancy, antidepressants, mood stabilizers

(*J Clin Psychopharmacol* 2014;34: 244–255)

From the *Department of Psychiatry and Obstetrics and Gynecology, †Depression Specialty Clinic, ‡Women's Mental Health Specialty Clinic, Center for Psychopharmacologic Research and Treatment, and §Psychosomatic Medicine, Women's Mental Health Specialty Clinic, University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester; and ||Department of Psychiatry, Perinatal and Reproductive Psychiatry Program, Harvard Medical School, Massachusetts General Hospital, Boston, MA.

Received May 12, 2011; October 7, 2013.

Reprints: Kristina M. Deligiannidis, MD, Women's Mental Health Specialty Clinic, Center for Psychopharmacologic Research and Treatment, University of Massachusetts Medical School, UMass Memorial Medical Center, 55 Lake Ave, N, Worcester, MA 01655 (e-mail: kristina.deligiannidis@umassmemorial.org).

Copyright © 2014 by Lippincott Williams & Wilkins

ISSN: 0271-0749

DOI: 10.1097/JCP.0000000000000087

Untreated mood disorders during pregnancy are associated with health risks to both mother and fetus, making the goal of euthymia paramount.^{1–4} Guidelines for the management of major depressive disorder and bipolar disorder during pregnancy stress the importance of preconception treatment planning and close clinical monitoring.^{2,5} Most women who discontinue maintenance antidepressants or mood-stabilizer pharmacotherapy for a pregnancy will experience a relapse during the pregnancy. Therefore, immediate and prophylactic treatment of many women with mood disorders will include pharmacologic treatment.^{6,7} Treatment during pregnancy is complicated by pharmacokinetic changes, which can result in lowered psychotropic drug levels and/or treatment efficacy.

Therapeutic drug monitoring (TDM) is an integral aspect of the standard of care for medications with established therapeutic ranges, a narrow therapeutic index or significant pharmacokinetic variability, which includes some mood stabilizers and tricyclic antidepressants (TCAs). Given the evidence for changes in perinatal physiology and pharmacokinetics, TDM has the potential to optimize dosing by avoiding supratherapeutic doses that would increase drug exposure to the mother and fetus or subtherapeutic dosing that would expose the dyad to the consequences of undertreated psychiatric illness. A comprehensive discussion that includes the potential risks of undertreated mental illness for the mother and fetus, benefits of nonpharmacologic and potential risks, and benefits to psychopharmacologic treatment^{8–16} is essential to quality patient care. In cases of polypharmacy, TDM can be valuable in avoiding adverse effects due to drug-to-drug interactions. For medications without standardized therapeutic ranges, an individual woman's drug level at a time when she is clinically asymptomatic that can be used as a target serum drug level during pregnancy may be useful.^{17,18}

The objectives of this review are to summarize the evidence for changes in perinatal pharmacokinetics of psychotropic medications commonly used for mood disorders during pregnancy, consider the implications for clinical and TDM, and make clinical recommendations.

MATERIALS AND METHODS

The English-language literature indexed on MEDLINE/PubMed was searched for the period between 1966 and 2013 using the following key terms: *antidepressant, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, desvenlafaxine, duloxetine, bupropion, mirtazapine, trazodone, vilazodone, amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine, amoxapine, maprotiline, selective serotonin reuptake inhibitor (SSRI), selective norepinephrine reuptake inhibitor (SNRI), tricyclic, tetracyclic, mood stabilizer, antiepileptic, lithium, lamotrigine (LTG), carbamazepine (CBZ), valproic acid (VPA), pregnancy, prenatal, delivery, post-partum, female, gender, pharmacokinetics, dosing, therapeutic drug monitoring, and drug level.* Resultant articles were cross-referenced for other relevant articles not identified in

the initial search. Original observational studies, case reports, and case series that evaluated or described pharmacokinetic changes or TDM during pregnancy or the postpartum were included.

RESULTS

Pharmacokinetics During the Perinatal Period

The drug dose–effect relationship is complex, including not only interperson pharmacokinetic and pharmacodynamic variability but also genetic variability controlling the translation of proteins involved in metabolizing enzymes, drug transporters, and drug targets. Small-to-moderate sex differences, which exist in drug absorption, distribution, metabolism, and elimination,^{19–21} may be amplified during pregnancy. For example, women have a slower gastric emptying²² and small bowel and colonic transit time when compared with men, which are further slowed during pregnancy.^{23,24} The increased plasma volume, change in protein binding, and lower ratio of lean muscle to adipose tissue in pregnant women may result in a greater volume of drug distribution for lipophilic drugs. Together, these changes likely contribute to a small effect in the peak plasma concentrations.¹⁹ Hepatic clearance of psychotropic medications is also altered, most notably due to pregnancy-associated changes in metabolic enzymes. Of the multiple families of metabolic enzymes,²⁵ the phase I metabolism cytochrome P450 (CYP) family has been best studied in pregnancy. Individual drugs often undergo metabolism by several CYP and/or non-CYP pathways. Other families of enzymes include phase 2 metabolism enzymes such as uridine diphosphate glucuronosyltransferase (UGT) and *N*-acetyltransferase. Increased sex steroids associated with pregnancy may modulate several of the CYP450 and UGT isoforms in a clinically relevant manner. Synthetic analogs of sexsteroids associated with pregnancy, such as those used in hormone replacement therapy or oral contraceptives, modulate several CYP450 isoforms via inhibition (CYP1A2,²⁶ CYP2C19,²⁷ CYP2B6,²⁸ and CYP3A4²⁹), induction (CYP2A6³⁰), or increasing glucuronidation by UGT1A4 and possibly UGT2B7.^{31,32} Cytochrome P450 and UGT changes may also have effects on adverse effect burden for both mother and fetus/infant because drug exposure partially depends on metabolism. Changes in maternal drug pharmacokinetics in conjunction with placental transfer and fetal drug metabolism affect fetal psychotropic drug exposure.^{33–41}

Cytochrome P1A2 is less active in women compared with men⁴² and is inhibited by sex steroids.^{43,44} The activity of CYP1A2 is reduced by 65% to 70% at the end of pregnancy compared with the postpartum period³² and may affect psychotropics metabolized by CYP1A2 including fluvoxamine, duloxetine, amitriptyline, clomipramine, desmethylimipramine, imipramine, and doxepin.

Greater CYP3A4 activity in women (via progesterone effects)^{42,45} has the potential to accelerate metabolism and reduce plasma levels of some commonly used psychotropics partially metabolized via CYP3A4 including citalopram, escitalopram, fluoxetine, paroxetine, trazodone, venlafaxine, desvenlafaxine, bupropion, mirtazapine, amitriptyline, clomipramine, imipramine, trimipramine, doxepin, and CBZ.

During pregnancy, CYP2C19 activity is reduced by almost 50%.⁴⁶ Pharmacokinetic changes associated with CYP2C19 during pregnancy may affect the metabolism of citalopram, escitalopram, sertraline, fluoxetine, vilazodone, venlafaxine, amitriptyline, clomipramine, trimipramine, imipramine, and desmethylimipramine.⁴⁷

Cytochrome P2D6 is generally induced during pregnancy,^{32,48} and CYP2D6-associated pharmacokinetic changes may affect the metabolism of numerous psychotropics from the SSRIs, SNRIs, and TCA drug classes. Maternal CYP metabolic phenotype (eg,

poor, intermediate, extensive, and ultrarapid) is an important determinant of metabolism. Different allelic forms of CYP2D6 may result in differing therapeutic dosing requirements. In nonpregnant patients, dose adjustments may be required based in part on CYP2D6 phenotype.⁴⁹ In pregnancy, phenotype influences metabolic ratios of medications biotransformed by CYP2D6.⁴⁸

Increased renal blood flow and the associated increase in glomerular filtration rate (GFR) may increase drug (eg, lithium) elimination during pregnancy.⁵⁰ Although the studies are inconsistent,^{51,52} increased hepatic blood flow may account for increased clearance and decreased concentration of high extraction ratio drugs during pregnancy.

The postpartum period is characterized by a rapid decline in sex steroid levels, contraction of plasma volume, reestablishment of hepatic enzyme activity after a period of metabolic refractory activity,^{53–56} and a return of the GFR to prepregnancy levels. As a consequence, increased drug blood levels may result and manifest as adverse effects of toxicity, especially when an increased dose used during pregnancy is continued into the postpartum.⁵⁷

In addition to changes in maternal pharmacokinetics, patient-specific psychologic factors and physiologic effects of pregnancy on vulnerability and treatment responsiveness may also influence treatment outcomes. Pregnancy brings about a psychosocial context, which differs among women, aspects of which can affect the risk of mood disorder recurrence during pregnancy or treatment efficacy.⁵⁸ Physiologic changes associated with pregnancy may interact with underlying sexual dimorphisms in the localization and concentration of endogenous neurotransmitters and their degradative enzymes and transporters, having the potential to clinically affect antidepressant pharmacodynamics (eg, drug-receptor interactions), particularly if they are sex steroid hormone responsive.^{59–62}

Evidence for Change in Perinatal Phase I Metabolism: SSRIs

Some women will experience increased metabolism of SSRIs in late pregnancy and may require higher dosing, especially during the third trimester to maintain clinical benefits. Fluoxetine is predominantly metabolized by CYP2C9 to its active metabolite norfluoxetine, which is also pharmacologically active.^{63,64} CYP3A4, CYP2D6, and CYP2C19 additionally contribute to fluoxetine's metabolism.^{63–67} Mean fluoxetine-metabolite ratio levels decrease between 20 to 26 weeks and 30 to 36 weeks' gestation, suggesting increased clearance during pregnancy, whereas postpartum fluoxetine-metabolite ratio levels increase, suggesting reduced clearance after delivery.⁵⁶ Similarly, higher maternal serum concentrations of fluoxetine and norfluoxetine in the postpartum period, compared with the third trimester, have been reported in women taking the same fluoxetine dose during both periods.⁶⁸ Decreased albumin levels in pregnancy may result in low plasma trough concentrations of highly protein-bound fluoxetine and norfluoxetine. Pregnancy-associated induced demethylation of fluoxetine by CYP2D6 may contribute to lower trough levels in pregnancy compared with the postpartum period.⁶⁹

Sertraline and its main weakly active metabolite *N*-desmethylsertraline are substrates of several P450 enzymes, including CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Sertraline dose increases are often required early in the third trimester to treat emergent depressive symptoms or maintain euthymia⁷⁰ with some women experiencing increased drug metabolism from second to third trimester.⁷¹

Paroxetine has no known pharmacologically active metabolites and is predominantly metabolized via CYP2D6 and to a lesser extent via CYP3A4.⁷² Steadily decreasing plasma levels

of paroxetine and increasing depressive symptoms can occur in pregnancy in women with the CYP2D6-extensive or ultrarapid metabolizer genotype. Cytochrome P2D6 intermediate and poor metabolizers may have increasing plasma levels of paroxetine throughout pregnancy.⁷³ Antidepressant accumulation in poor and intermediate metabolizers could potentially have adverse effects on the fetus.⁷⁴

Citalopram, a racemic mixture of *R*- and *S*-citalopram, and the more pharmacologically active *S*-enantiomer, escitalopram, are metabolized via demethylation at CYP2C19, CYP2D6, and CYP3A4.^{75,76} Main metabolites include desmethylcitalopram and didesmethylcitalopram. Doses of citalopram result in low trough plasma concentrations and metabolites during pregnancy but a significantly higher mean desmethylcitalopram-citalopram metabolic ratio compared with 2 months postpartum, suggesting induced metabolism during pregnancy.⁵³ Decreased level/dose ratios are associated with lowered drug efficacy and increased dose requirements in the second half of gestation.⁵⁵ Enhanced demethylation of citalopram by CYP2D6 may in part contribute to lower trough levels in pregnancy as compared with the postpartum period.^{53,77}

Fluvoxamine is an achiral drug without clinically significant active metabolites. It undergoes metabolism via CYP2D6 and CYP1A2, and its main metabolite is fluvoxamine acid.⁷⁸ Pharmacokinetic studies during pregnancy were not found for fluvoxamine, but CYP2D6 activity has been shown to be increased during the third trimester and associated with decreased plasma drug concentrations and possibly diminished efficacy. This effect may be offset by the decreased CYP1A2 activity seen throughout pregnancy.³²

Vilazodone is metabolized through CYP, mainly CYP3A4 with lesser contributions from CYP2C19 and CYP2D6, and non-CYP pathways.⁷⁸ Pharmacokinetic studies during pregnancy were not found for vilazodone, but the 2 main CYP isoenzymes responsible for its metabolism demonstrate different overall changes in activity during pregnancy (ie, CYP2C19 is reduced, and CYP2D6 is increased). The net effect of these changes on vilazodone during pregnancy is unknown.

Evidence for Change in Perinatal Phase 1 Metabolism: SNRIs

Venlafaxine is renally excreted and predominantly metabolized by CYP2D6 into *O*-desmethylvenlafaxine (ie, desvenlafaxine) and CYP3A4 to *N*-desmethylvenlafaxine. Although dose adjustments for sex are not generally indicated, women have higher dose-corrected concentrations than men.^{79,80} An analysis that compared venlafaxine and its metabolic products in the first and third trimester to the postpartum period did not find concentration differences.⁷⁷ In contrast, 1 case report of a pregnant adolescent patient with bipolar II disorder treated with venlafaxine extended release and concomitant psychotropics reported 2-fold higher venlafaxine plasma levels in the postpartum than during pregnancy for the same dose.⁵⁷

Unlike venlafaxine, desvenlafaxine is metabolized by CYP3A4 and is biotransformed to *N,O*-didesmethylvenlafaxine and a hydroxylated metabolite.⁸¹ No pharmacokinetic studies during pregnancy were located for desvenlafaxine, but based on studies of CYP3A4 with other antidepressants, its metabolism has the potential to be reduced during pregnancy.

Duloxetine undergoes oxidative metabolism to 4-, 5-, and 6-hydroxy duloxetine by CYP2D6 and CYP1A2 and subsequent sulfate and glucuronide conjugation.⁸² Nonpregnant women have a 64% higher average steady-state concentration than men, in part because of lower CYP1A2 activity in women.⁸³ No pharmacokinetic studies during pregnancy were located for duloxetine;

however, 1 study reported duloxetine plasma levels in healthy lactating postpartum women comparable with those observed in healthy adults.⁸⁴

Evidence for Change in Perinatal Phase 1 Metabolism: Other Antidepressants

Bupropion is extensively metabolized in the liver primarily by CYP2B6 to its main active metabolite, hydroxybupropion, and to threo- and erythrohydrobupropion via carbonyl reduction. During pregnancy, the placenta is a site of bupropion biotransformation, although carbonyl reduction is favored over oxidative biotransformation at this tissue site.^{38,85,86} To a lesser extent, the CYP1A2, 2A6, 2C9, 2D6, 2E1, and 3A4 isoforms are also involved in bupropion metabolism.^{87–89} Sex hormones inhibit up to 50% of bupropion hydroxylation via CYP2B6,²⁸ but the isoform shows high interindividual variability.⁹⁰ No systematic studies have been published that inform the pharmacokinetics or TDM for bupropion in pregnancy.

Mirtazapine is a tetracyclic antidepressant that is rapidly and completely absorbed. Major pathways of biotransformation include demethylation and oxidation followed by conjugation. Mirtazapine undergoes *N*-demethylation via CYP3A4 into the pharmacologically active desmethylmirtazapine and hydroxylation by CYP2D6 and CYP1A2. Because several metabolic pathways contribute to mirtazapine's biotransformation, genetic polymorphisms affecting activity in any one of the pathways are not hypothesized to result in clinically significant changes in mirtazapine plasma concentrations^{91–93}; however, CYP2D6 genotype may influence the concentrations of the enantiomers of mirtazapine and its metabolites.⁹⁴ Nonpregnant women exhibit longer elimination half-lives and a 15% lower drug disposition as compared with men.⁹⁵ Women show higher plasma concentrations compared with men,⁹⁴ but it is unknown if this results in differences in clinical efficacy. No pharmacokinetic studies during pregnancy were located for mirtazapine.

Trazodone is highly lipophilic, well absorbed, and extensively metabolized by the liver via hydroxylation, *N*-oxidation and *N*-dealkylation. Cytochrome P3A4 mediates the *N*-dealkylation that results in the formation of the active metabolite 1-*m*-chlorophenylpiperazine, which then undergoes hydroxylation by CYP2D6.⁹⁶ Therapeutic response has been associated with plasma trazodone concentrations of approximately 700 ng/mL but not with 1-*m*-chlorophenylpiperazine⁹⁷ plasma levels. Cytochrome P1A2 may also be involved in trazodone metabolism. Higher drug concentrations have been found in females⁹⁸ as compared with men. Pharmacokinetic data are limited to 1 case report of a pregnant patient treated with trazodone extended release of 150 mg/d in conjunction with other psychotropics. Plasma trazodone drug levels and the elimination half-life remained stable throughout pregnancy.⁵⁷

Evidence for Change in Perinatal Metabolism: TCA

Tricyclic antidepressants metabolism is complex, and the pharmacokinetic changes observed in pregnancy likely reflect a summation of multiple metabolic effects including phase 1 and 2 metabolism. Generally, tertiary TCAs are demethylated by varying CYP450 enzymes into secondary TCAs and then undergo hydroxylation by CYP2D6 and glucuronidation by UGT. No pharmacokinetic or TDM studies during pregnancy were located for amitriptyline, desipramine, doxepin, protriptyline, trimipramine, amoxapine, or maprotiline.

A landmark study by Wisner et al⁹⁹ (1993) evaluated nortriptyline, clomipramine, and imipramine levels during pregnancy compared with nonpregnancy doses and levels. The final dose

required during pregnancy to maintain therapeutic drug levels was an average of 1.3 to 2.0 times the dose required when not pregnant. Doses increased over the second half of pregnancy, especially in the third trimester. The third trimester was associated with rapid acceleration of the required dose increase,⁹⁹ and patients responded at plasma levels similar to those before pregnancy. Subsequent case reports of decreased plasma levels of nortriptyline and imipramine during pregnancy associated with recurrence of depressive symptoms confirm these findings.¹⁰⁰ Nortriptyline level/dose ratios rise during the 2 to 6 postpartum weeks and then decline and stabilize around week 11 and beyond (Table 1).⁵⁴

Evidence for Change in Perinatal Metabolism of Mood Stabilizers: Lithium, LTG, CBZ, and VPA

Lithium

Although effects of pregnancy on the pharmacokinetics of antidepressant metabolism are variable, pregnancy more clearly affects the pharmacokinetics of lithium and some antiepileptic drugs (AEDs). Lithium is rapidly absorbed through the upper gastrointestinal tract and is almost exclusively renally eliminated without undergoing biotransformation. It is filtered through the glomeruli as a free ion, and 80% is reabsorbed by the proximal

tubule.^{102,103} The pharmacodynamics of lithium is influenced by weight, renal function, age, coadministered medications, pregnancy, and lactation.^{102,104} If the excretion of lithium is impaired, plasma ion concentrations can increase dramatically and precipitate toxicity.¹⁰³ Lithium has an established therapeutic drug level and a narrow therapeutic index of 0.6 to 1.2 mEq/L. Lithium clearance is 20% to 30% of the GFR and thus varies with GFR. During pregnancy, lithium increases by 30% to 50% because of increased renal blood flow and GFR, particularly in the last months of gestation,^{50,104,105} causing plasma levels to decrease substantially, increasing the risk of maternal relapse.¹⁰⁶ At delivery, vascular volume rapidly decreases, and lithium clearance precipitously decreases to prepregnancy levels.^{102,107}

Lamotrigine

Lamotrigine is the most widely prescribed AED for epilepsy in women of reproductive age¹⁰⁸ and is often used for maintenance treatment of bipolar disorder. Lamotrigine almost entirely undergoes hepatic glucuronic acid conjugation to its inactive metabolite LTG 2-*N*-glucuronide via UGT1A4. The sex steroid changes that occur in pregnancy increase phase 2 glucuronidation, which leads to increased LTG clearance.^{109,110} 2-*N*-glucuronide/LTG ratios are reported to be 175% higher in the third trimester

TABLE 1. Change in Perinatal Antidepressant Phase 1 Metabolism and Indications for Perinatal Dose Adjustments

Antidepressant	Main Isoenzymes Involved in Metabolism ¹⁰¹	Evidence of Change in Metabolism in Pregnancy
Dose increase may be indicated after 20 weeks gestation		
Citalopram	CYP19, CYP2D6, CYP3A4	Increased drug metabolism between 20 weeks and delivery. ^{53,55}
Clomipramine	CYP1A2, CYP2C19, CYP2D6, CYP3A4	Decreased plasma levels ^{99,100}
Imipramine	CYP1A2, CYP2C19, CYP2D6, CYP3A4	Decreased plasma levels ⁹⁹
Dose increase may be indicated in third trimester		
Fluoxetine	CYP2C9, CYP2C19, CYP2D6, CYP3A4	Higher maternal serum concentrations in the postpartum period compared with the third trimester ^{68,69} ; mean ratios of fluoxetine to metabolite levels decreased during pregnancy. ⁵⁶
Fluvoxamine	CYP1A2, CYP2D6	Increased CYP2D6 activity in third trimester ³²
Nortriptyline	CYP2D6	Decreased plasma levels ^{99,100}
Paroxetine	CYP2D6, CYP3A4	Plasma levels may increase or decrease, varies with metabolizer genotype. ^{73,74}
Sertraline	CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4	Marked heterogeneity in range of pharmacokinetic changes ^{70,71}
Dose adjustments generally not indicated		
Venlafaxine	CYP2D6, CYP2C19, CYP3A4	Metabolism consistent across pregnancy and the postpartum ⁷⁷ ; report of 2-fold increase plasma level in postpartum ⁵⁷
Insufficient data on need for dose adjustment		
Amitriptyline	CYP1A2, CYP2C19, CYP2D6, CYP3A4	
Bupropion	CYP2B6, CYP2D6, CYP1A2, CYP2A6, CYP2C9, CYP2E1, CYP3A4	
Desipramine	CYP2D6	
Desvenlafaxine	CYP3A4	
Doxepin	CYP1A2, CYP2D6, CYP2C19, CYP3A4	[Insufficient data for change in metabolism in pregnancy.]
Duloxetine	CYP1A2, CYP2D6	
Mirtazapine	CYP1A2, CYP2D6, CYP3A4	
Trazodone	CYP3A4	
Trimipramine	CYP2C19, CYP2D6, CYP3A4	
Vilazodone	CYP3A4, CYP2C19, CYP2D6	

than at baseline. Less significant pregnancy-induced changes can also affect LTG levels, such as the degree of plasma protein binding, absorption, or transplacental transfer.^{109,111}

Although there is substantial variability in the pharmacokinetics of LTG among women,^{112–114} plasma concentrations consistently decline in pregnancy.^{17,113–117} Lamotrigine clearance increases substantially at pregnancy onset¹¹⁸ and continues to increase progressively through the third trimester.^{17,18,113} Lamotrigine clearance potentially increases greater than 330% between preconception and the third trimester. An average dose increase of 250% is required to sustain therapeutic drug levels across pregnancy in women with epilepsy.¹¹³ Beginning within days of delivery and continuing during the first weeks postpartum, LTG elimination rate drops rapidly and plasma concentrations increase dramatically.^{109,113,115,116,119}

Carbamazepine

Carbamazepine is metabolized hepatically mainly via conversion to an active metabolite, 10,11-epoxide. The 10,11-epoxide is then metabolized to inactive compounds via glucuronidation, conjugation, and hydroxylation. Carbamazepine induces the P450 system, which can increase the metabolism of medications administered concurrently.¹²⁰ Carbamazepine clearance seems to increase in pregnancy,¹²¹ with some studies reporting declining total concentrations of CBZ during the second and third trimester,^{122–127} whereas others have not found a significant change in CBZ plasma clearance.¹²⁸ A study of 22 pregnancies reported a 42% decline in total plasma level and a 22% decline in free concentration.¹²⁹ The measurement of total plasma concentrations of CBZ may be misleading, given that studies suggest that although the total concentration of CBZ decreases significantly in pregnancy, free-CBZ levels may not change when compared with baseline^{123,129} until delivery.¹²⁹ The decrease in protein binding is likely the cause of the decrease in total CBZ concentration because the free concentration is less affected.¹²⁹

Valproic Acid

Of all the mood stabilizers, VPA has the greatest risk of teratogenicity including neural tube defect and neurocognitive impairment^{15,16} and should not be considered a first-line mood stabilizer in women of reproductive potential. However, VPA is often prescribed to women of childbearing age.¹³⁰ If the decision is made that VPA is the appropriate medication for perinatal mood stabilization, despite the risks, a number of measures can be taken to minimize fetal risk.

Highly protein bound, VPA pharmacologic activity is due to the free or unbound drug that crosses the blood-brain barrier. Valproic acid metabolism is complex because it undergoes a variety of different metabolic processes including mitochondrial beta-oxidation, CYP450-dependent processes including CYP2C9, CYP2C19, and CYP2A6, and glucuronidation. The half-life of VPA can be altered dramatically when administered with other medications that affect these pathways.¹²⁰

An increase in VPA clearance resulting in a decrease in serum VPA levels has been observed particularly at the end of the third trimester.^{128,131–133} The plasma concentration of VPA decreases by as much as 50% in the last few weeks of pregnancy; however, no significant changes have been found in unbound concentrations.^{131,134} Concentration-dependent, VPA plasma protein binding decreases during pregnancy, and the free fraction increases as serum concentrations rise.¹³⁴ Although VPA is highly protein bound, several authors^{133–136} have noted that while the total VPA levels decline, free levels do not and in fact remain unchanged or even increased. This suggests that both free and total plasma levels of VPA should be measured

during pregnancy.^{134,135} Valproic acid concentration decreases sharply in the immediate postpartum period (Table 2).¹³¹

DISCUSSION AND CLINICAL RECOMMENDATIONS

Antidepressants

The relationships between drug dose, TDM, and therapeutic effects are complex. Interindividual differences result from pharmacokinetic and pharmacodynamic variability, as well as genetic variants influencing the translation of proteins involved in metabolizing enzymes, drug transporters, and drug targets. At the level of the individual, perinatal changes in pharmacokinetics may or may not lead to changes in drug or metabolite levels. In addition, changes in drug or metabolite levels do not necessarily lead to alterations in clinical status.

Although SSRI concentrations fluctuate in pregnancy, the relationship between SSRI blood levels and clinical response is not well established.^{142–144} Despite the lack of clarity in the relationship between SSRI blood levels and clinical response, data suggest that many pregnant women on antidepressant monotherapy may require dose increases, especially after 20 weeks gestation,⁷⁰ to treat depressive symptoms or maintain euthymia. Studies to date suggest broad interindividual variability in pharmacokinetic changes, with some but not all women experiencing faster SSRI metabolism in late pregnancy. To maintain euthymia for some women in late pregnancy, the SSRI dose may need to be increased almost 2-fold the dose required earlier in pregnancy.⁷⁰ Based on population data, at this time, there is insufficient evidence to support routine therapeutic blood level monitoring of antidepressants other than TCAs during pregnancy or the postpartum. Therapeutic drug monitoring is especially helpful with the TCA class, not only to monitor efficacy but also toxicity. Clinical presentation, ideally in combination with the use of measurement-based care using standardized assessments^{145–147} during the perinatal period, should primarily inform treatment decisions.

Although not studied with most non-TCA antidepressants, a potential patient-specific option is to use the individual woman's antidepressant level at a time when she is clinically asymptomatic as a target serum level during pregnancy. Although these antidepressants do not have an established therapeutic range, the individual woman's antidepressant level can be used as a guide for adjusting dosage during pregnancy and in the postpartum. However, studies are necessary to determine if this strategy would improve clinical care and whether it would be cost-effective. In 2004, the Food and Drug Administration suggested that physicians may consider tapering antidepressants in the third trimester to lower the risk of complications associated with late gestational exposure to SSRIs;¹⁴⁸ however, research does not support that discontinuing antidepressants in the third trimester diminishes the risk for neonatal symptoms.¹⁴⁹ Postpartum pharmacokinetic changes can result in the emergence of antidepressant adverse effects soon after delivery for women who are required for a dose increase during pregnancy. We recommend close clinical monitoring; if adverse effects emerge, the dosage can be lowered. We do not recommend immediately decreasing the antidepressant to the preconception dose in the absence of adverse effects.

Standards have been established for TDM for TCAs outside the perinatal period, and these serve as a basis for the measurement and interpretation of perinatal drug levels. During pregnancy, we recommend monthly monitoring of trough drug levels. Monitoring is especially important in the third trimester when dose increases may be necessary. In the postpartum period, we recommend careful monitoring for adverse effects and tapering to the preconception dose to mitigate adverse effects that may

TABLE 2. Change in Perinatal Metabolism of Mood Stabilizers and Recommendations for TDM or Dose Adjustments

Mood Stabilizer	Main Mechanisms of Metabolism	Evidence of Change in Metabolism in Pregnancy	Recommendations for Clinical Monitoring and TDM
Lithium	GI absorption Excreted via urine	Increased renal blood flow and GFR ^{50,105} Increased renal lithium clearance ¹³⁷ Lower serum concentrations ^{137,138}	TDM up to monthly during pregnancy and up to weekly or biweekly in the last month of pregnancy ^{106,138} for women who are required for reinitiation of lithium and have unstable mood symptoms or concurrent medical conditions affecting lithium serum concentrations TDM each trimester for euthymic women on stable doses of lithium Maintain lowest effective level. ¹³⁹ Check maternal lithium level before delivery. Check therapeutic drug levels immediately after delivery and for any clinical worsening or change in clinical status related to obstetrical, medical, and psychiatric condition. ¹³⁸ Once medically stable, restart preconception dose.
LTG	Hepatic glucuronic acid conjugation via UGT1A4	Increased phase 2 glucuronidation ¹⁰⁹ LTG clearance increases and plasma concentration decreases across pregnancy. ^{109,111,112,114–116,118} Postpartum LTG elimination rate drops rapidly. ^{109,113,115,116}	Mean dose increase of 250% required to sustain therapeutic drug levels across pregnancy in women with epilepsy ¹¹³ Use option preconception drug level as a guide for adjusting dosage. ¹⁴⁰ Use lowest effective dose ¹⁵ Empirically taper to preconception dose in the postpartum period ^{111,113,116}
CBZ	CYP3A4, CYP2B6, CYP2C8, CYP2E1, CYP2C9, CYP1A2, UGT Excreted via urine (72%) and feces (28%)	Data are conflicting; CBZ clearance may increase in pregnancy, whereas total CBZ concentration decreases significantly in pregnancy. ^{122–127} Free CBZ levels do not change when compared with baseline ^{123,129} until delivery. ¹²⁹	Both free and plasma concentrations should be monitored. ^{122–124,129} Lowest effective dose should be used. ¹⁵ After delivery, the dose should be tapered rapidly to avoid toxicity buildup and maintain prepregnancy CBZ levels.
VPA	Highly protein bound; complex hepatic metabolism via mitochondrial beta-oxidation, CYP450 (eg, CYP2C9, CYP2C19, and CYP2A6), and glucuronidation	Plasma concentration decreases. ^{128,131–133} No significant changes in free or unbound concentrations in pregnancy. ^{131,134} Sharp decrease in VPA concentration in the immediate postpartum period ¹³¹	Both free and total plasma levels of VPA should be measured during pregnancy. ^{134,135} Baseline VPA levels should be obtained before conception to identify the optimal serum concentration for mood stabilization. Use optimal drug level to dose adjustments during pregnancy. Levels should be checked at least monthly to maintain the preconception serum concentration. ¹⁴¹ After delivery, the dose should be tapered rapidly to avoid toxicity buildup and to maintain preconception VPA levels.

GI indicates gastrointestinal.

be associated with rising serum levels 2 to 6 weeks after delivery. We recommend checking a blood level whenever adverse effects emerge in the early postpartum or at least at week 6 when drug levels have been reported to peak before eventual stabilization around week 11.⁵⁴ Dose decreases may be indicated around week 6 to ameliorate adverse effects.

Mood Stabilizers

Women with bipolar disorder are at a heightened risk of relapse in the postpartum,¹⁵⁰ and therefore, clinical monitoring and optimization of treatment is imperative in late pregnancy and early

postpartum. Pregnancy markedly affects the pharmacokinetics of both LTG and lithium, with plasma concentrations declining throughout pregnancy.^{17,113–116} Therapeutic drug monitoring of AEDs is common in the treatment of epilepsy during pregnancy and may also be useful in the treatment of bipolar disorder during the perinatal period.

Therapeutic drug monitoring for lithium is well established, and in pregnancy, renal lithium clearance almost doubles, lowering serum concentrations and increasing the potential for relapse.¹³⁷ Several authors^{106,138} recommend frequent TDM of lithium in pregnancy, up to monthly during pregnancy and up to

weekly or biweekly in the last month of pregnancy. This frequency of monitoring may be indicated in women who have discontinued lithium and require reinitiation of the drug or in women with medical comorbidities affecting lithium absorption or clearance, such as hyperemesis gravidarum or dehydration. For euthymic women on stable doses of lithium, we recommend checking a lithium level every trimester. Although 0.8 to 1.0 mEq/L is widely cited as a target effective level,¹⁵¹ during pregnancy, women should be maintained at the lowest effective level.¹³⁹ Therapeutic drug monitoring can also be used to prevent women from lithium toxicity that can occur during immediate changes in physiology from acute illnesses such as gastroenteritis or other causes of volume depletion including hyperemesis gravidarum.¹⁴ Although the evidence is equivocal, some authors recommend a sustained-release preparation during pregnancy¹⁵² because they are often thought to produce more stable lithium levels than immediate release preparations.¹⁰⁴

A maternal lithium level should be checked when women present for delivery, and adequate hydration should be ensured; nephrotoxins and nonsteroidal antiinflammatory drugs should be avoided.¹⁵³ Although some authors have recommended holding lithium at labor onset^{137,139} or 24 to 48 hours before a scheduled cesarean delivery or induction,^{104,106,107,139} this has not been found to mitigate adverse perinatal outcomes and infant complications. Others have recommended increasing hydration around delivery to avoid lithium toxicity.¹⁰⁴ Therapeutic drug levels should be checked 24 hours after delivery and then after each dose adjustment.¹³⁸

At delivery, the risk of some lithium-induced perinatal complications may also be related to neonatal serum levels, especially for levels greater than 0.64 mEq/L.¹³⁹ Thus, using the lowest effective dose that is still within therapeutic range is recommended.¹⁴ If neonatal lithium toxicity is suspected, the neonate's serum lithium level should be monitored. Lithium containing sampling devices should be avoided because they can yield inaccurate lithium levels.^{154,155} Maternal GFR returns to pregravid levels immediately after delivery, and lithium levels return to preconception levels.¹³⁹ Vascular volume rapidly decreases by approximately 40% and renal lithium clearance decreases to prepregnancy levels, leading to increased serum concentrations and risk of maternal lithium toxicity;^{106,107,156} thus, preconception doses should be restarted immediately after delivery.¹⁴

The American Academy of Neurology states that evidence supports active monitoring of LTG levels during pregnancy.¹¹⁴ In view of the interpatient variability, some authors recommend the establishment of a baseline LTG concentration in any woman of childbearing age with epilepsy^{116,118} and at least monthly monitoring during pregnancy and weekly during puerperium.^{113,118} In contrast to the use of LTG in the treatment of epilepsy, LTG dosing in bipolar disorder is typically guided by clinical response. Blood levels are not routinely obtained, and target therapeutic blood levels are not defined because they are for other mood stabilizers such as lithium and VPA. However, an individual's preconception level could potentially be used as a guide for prophylactically increasing dosage during pregnancy^{18,140,157} because LTG levels decline and potentially reduce risk of relapse and postpartum psychosis.^{140,158–160}

If a preconception LTG level is not available for reference, increases in LTG dosing in late pregnancy should be driven by clinical response with a low threshold for increased dosage. Postpartum LTG toxicity is common and can occur in more than 25% of women, whereas LTG's elimination rate drops rapidly and plasma concentrations increase dramatically immediately after delivery until 2 to 3 weeks postpartum.^{109,113,115,116} Empirically tapering to the preconception dose in the postpartum period can reduce toxicity.^{111,113,116}

For women receiving CBZ, both free and plasma concentrations should be monitored^{122–124,129} in combination with close clinical monitoring; both should guide dose adjustments.¹²⁹ Similar to the other mood stabilizers, the lowest effective dose should be used in pregnancy. After delivery, the dose should be tapered rapidly to avoid toxicity and maintain prepregnancy CBZ levels.

For women who plan to conceive while using VPA for mood stabilization, baseline VPA levels should be obtained before conception to identify the optimal serum concentration for mood stabilization and guide the dose adjustments during pregnancy. Free and plasma levels should be checked at least monthly to maintain the preconception serum concentration.¹⁴¹ Valproic acid easily transfers across the placenta, and congenital malformations correlate with maternal VPA concentrations and daily dose.^{131,161–163} The lowest effective dosage of VPA, preferably less than 1000 mg/d, should be used in pregnancy.¹³⁵ To decrease the incidence of neural tube defects, all women of childbearing age taking most anticonvulsants should be treated with up to 4 to 5 mg/d of folic acid. After delivery, the dose should be tapered rapidly to avoid toxicity buildup and to maintain preconception VPA levels.

Therapeutic drug monitoring can also be used to mitigate some of the risks associated with drug interactions, which lithium, LTG, VPA, and CBZ are all very sensitive to. Therapeutic drug monitoring is imperative to monitor for changes in lithium levels that can occur secondary to drug-to-drug interactions. Lamotrigine, VPA, and CBZ are AEDs that can induce or inhibit other drugs and thereby diminish or enhance the pharmacologic effect of other drugs. Carbamazepine induces enzyme activity and thus decreases drug concentrations and the effect of other drugs. In contrast, VPA inhibits enzyme activity and increases drug concentrations, which carries the risk of causing drug toxicity. Therapeutic drug monitoring can be used to monitor drug concentrations and optimize treatment.¹⁶⁴

Further Recommendations for Clinical Care

The use of antidepressant or mood-stabilizing medications during pregnancy involves complex clinical decisions based on the risks and benefits of medications as well as clinical status, history, and treatment preferences of each woman.^{4,5,106,113,139,165} Data-driven clinical recommendations for frequency of clinical monitoring and TDM across pregnancy and the postpartum are urgently needed, whereas therapeutic ranges have typically been derived in nonpregnant populations and have not yet been validated in pregnancy.¹⁶⁶ The available data support frequent clinical monitoring of symptoms throughout pregnancy and postpartum; therefore, this is strongly recommended.

Further research is critically needed to examine how TDM of antidepressants and mood stabilizers in pregnancy will inform the efficacy and safety of psychotropic use for women and their infants. The literature reflects great interindividual variability regarding the effects of pregnancy on metabolism of medications where such data are available. Research is required to identify biomarkers that would specifically inform which women are at risk for clinically significant pharmacokinetic changes in their medications across pregnancy and postpartum.

AUTHOR DISCLOSURE INFORMATION

Dr Deligiannidis has received research support from UMass Medical School (NIH UL1RR031982), NIH (NIMH 1K23MH097794), Worcester Foundation for Biomedical Research, and Forest Research Institute and royalties from an employee invention (National Institutes of Health/National Institute of Child Health and Human Development). Dr Byatt has also received grant/funding support from the Massachusetts Department of Mental Health for

the Massachusetts Child Psychiatry Access Program for Moms, Meyers Primary Care Institute and the Rosalie Wolf Interdisciplinary Geriatric Healthcare Research Center Small Grants Initiative. Dr Byatt's work was on this project supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through grant number KL2TR000160. Dr Freeman has received research support from GlaxoSmithKline, Lilly, and Forest, has served on advisory boards or consulted for Johnson & Johnson, Genentech, Takeda and Lundbeck, Otsuka, and Pamab, and has received a stipend for medical editing from DSM Nutritionals.

REFERENCES

- Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. *Psychosom Med*. 2001;63(5):830–834.
- Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. *Gen Hosp Psychiatry*. 2009;31(5):403–413.
- Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. *Arch Gen Psychiatry*. 2010;67(10):1012–1024.
- Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. *Am J Psychiatry*. 2009;166(5):557–566.
- Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. *Am J Psychiatry*. 2004;161(4):608–620.
- Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. *JAMA*. 2006;295(5):499–507.
- Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. *Am J Psychiatry*. 2007;164(12):1817–1824; quiz 1923.
- Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. *Acta Psychiatr Scand*. 2013;127(2):94–114.
- 't Jong GW, Einaron T, Koren G, et al. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review. *Reprod Toxicol*. 2012;34(3):293–297.
- Yonkers KA, Norwitz ER, Smith MV, et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. *Epidemiology*. 2012;23(5):677–685.
- Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. *Am J Obstet Gynecol*. 2012;207(1):49.e1–49.e9.
- Bodén R, Lundgren M, Brandt L, et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. *BMJ*. 2012;345:e7085.
- Galbally M, Roberts M, Buist A. Mood stabilizers in pregnancy: a systematic review. *Aust N Z J Psychiatry*. 2010;44(11):967–977.
- Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. *Expert Opin Drug Saf*. 2012;11(3):425–437.
- Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. *Lancet Neurol*. 2011;10(7):609–617.
- Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. *Ann Epidemiol*. 2011;21(11):842–850.
- Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. *Neurology*. 2004;62(2):292–295.
- Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. *Neurology*. 2008;70(22 Pt 2):2130–2136.
- Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. *Am J Psychiatry*. 1992;149(5):587–595.
- Bies RR, Bigos KL, Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. *J Gen Specif Med*. 2003;6(3):12–20.
- Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. *Drugs*. 1995;50(1):1–6.
- Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. *Gastroenterology*. 1989;96(1):11–17.
- Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. *Scand J Gastroenterol*. 2003;38(1):36–42.
- Lorena SL, Tinois E, Hirata ES, et al. Scintigraphic study of gastric emptying and intragastric distribution of a solid meal: gender differences. *Arq Gastroenterol*. 2000;37(2):102–106.
- Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. 2007 2009 [cited 2011 April 17]; Available at: <http://medicine.iupui.edu/clinpharm/ddis/table.asp>. Accessed March 13, 2013.
- Balogh A, Klinger G, Henschel L, et al. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. *Eur J Clin Pharmacol*. 1995;48(2):161–166.
- Palovaara S, Tybring G, Laine K. The effect of ethinylestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. *Br J Clin Pharmacol*. 2003;56(2):232–237.
- Palovaara S, Pelkonen O, Uusitalo J, et al. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. *Clin Pharmacol Ther*. 2003;74(4):326–333.
- Palovaara S, Kivistö KT, Tapanainen P, et al. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. *Br J Clin Pharmacol*. 2000;50(4):333–337.
- Chang SY, Chen C, Yang Z, et al. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. *Drug Metab Dispos*. 2009;37(8):1667–1675.
- Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. *Epilepsia*. 2005;46(9):1414–1417.
- Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. *Clin Pharmacokinet*. 2005;44(10):989–1008.
- DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. *J Psychopharmacol*. 2006;20 (suppl 4):S4–S9.
- Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. *Clin Pharmacokinet*. 2004;43(8):487–514.

35. Wang JS, Newport DJ, Stowe ZN, et al. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. *Drug Metab Rev*. 2007;39(4):723–746.
36. Hakkola J, Raunio H, Purkunen R, et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. *Biochem Pharmacol*. 1996;52(2):379–383.
37. Ter Horst PG, Jansman FG, van Lingen RA, et al. Pharmacological aspects of neonatal antidepressant withdrawal. *Obstet Gynecol Surv*. 2008;63(4):267–279.
38. Earhart AD, Patrikeeva S, Wang X, et al. Transplacental transfer and metabolism of bupropion. *J Matern Fetal Neonatal Med*. 2010;23(5):409–416.
39. Heikkine T, Ekblad U, Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. *BJOG*. 2002;109(9):1003–1008.
40. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. *Am J Psychiatry*. 2003;160(5):993–996.
41. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. *Pharmacopsychiatry*. 2009;42(3):95–100.
42. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. *J Womens Health (Larchmt)*. 2005;14(1):19–29.
43. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. *J Clin Pharmacol*. 1999;39(9):936–940.
44. Lane JD, Steege JF, Rupp SL, et al. Menstrual cycle effects on caffeine elimination in the human female. *Eur J Clin Pharmacol*. 1992;43(5):543–546.
45. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. *Am J Obstet Gynecol*. 2005;192(2):633–639.
46. McGready R, Stepniewska K, Seaton E, et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. *Eur J Clin Pharmacol*. 2003;59(7):553–557.
47. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. *Cell Mol Neurobiol*. 1999;19(3):373–409.
48. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. *Clin Pharmacol Ther*. 1997;62(4):400–407.
49. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry*. 2004;9(5):442–473.
50. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. *Br J Obstet Gynaecol*. 1981;88(1):1–9.
51. Robson SC, Mutch E, Boys RJ, et al. Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. *Br J Obstet Gynaecol*. 1990;97(8):720–724.
52. Nakai A, Sekiya I, Oya A, et al. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. *Arch Gynecol Obstet*. 2002;266(1):25–29.
53. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. *Clin Pharmacol Ther*. 2002;72(2):184–191.
54. Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. *Psychopharmacol Bull*. 1997;33(2):243–248.
55. Sit DK, Perel JM, Helsel JC, et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. *J Clin Psychiatry*. 2008;69(4):652–658.
56. Sit D, Perel JM, Luther JF, et al. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. *J Clin Psychopharmacol*. 2010;30(4):381–386.
57. Klier CM, Mossaheb N, Saria A, et al. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. *J Clin Psychopharmacol*. 2007;27(6):720–722.
58. Grote NK, Frank E. Difficult-to-treat depression: the role of contexts and comorbidities. *Biol Psychiatry*. 2003;53(8):660–670.
59. Jiang H, Xie T, Ramsden DB, et al. Human catechol-O-methyltransferase down-regulation by estradiol. *Neuropharmacology*. 2003;45(7):1011–1018.
60. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. *Mol Pharmacol*. 1999;56(1):31–38.
61. Worda C, Sator MO, Schneeberger C, et al. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. *Hum Reprod*. 2003;18(2):262–266.
62. Sacher J, Wilson AA, Houle S, et al. Elevated brain monoamine oxidase A binding in the early postpartum period. *Arch Gen Psychiatry*. 2010;67(5):468–474.
63. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. *Psychopharmacology (Berl)*. 1997;132(4):402–407.
64. Liu ZQ, Shu Y, Huang SL, et al. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. *Acta Pharmacol Sin*. 2001;22(1):85–90.
65. Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. *J Clin Psychopharmacol*. 2001;21(3):330–334.
66. Margolis JM, O'Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. *Drug Metab Dispos*. 2000;28(10):1187–1191.
67. Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. *Basic Clin Pharmacol Toxicol*. 2005;97(5):296–301.
68. Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. *Br J Clin Pharmacol*. 2006;61(2):155–163.
69. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. *Clin Pharmacol Ther*. 2003;73(4):330–337.
70. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. *Depress Anxiety*. 2000;11(2):51–57.
71. Freeman MP, Nolan PE Jr, Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. *J Clin Psychopharmacol*. 2008;28(6):646–653.
72. JornilJ, JensenKG, LarsenF, et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. *Drug Metab Dispos*. 2010;38(3):376–385.
73. Ververs FF, Voorbij HA, Zwarts P, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. *Clin Pharmacokinet*. 2009;48(10):677–683.
74. Laine K, Kytölä J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. *Ther Drug Monit*. 2004;26(6):685–687.

75. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. *J Clin Psychopharmacol*. 1999;19(5 suppl 1):23S–35S.
76. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. *Clin Pharmacokinet*. 1993;24(3):203–220.
77. O'Brien L, Baumer C, Thieme D, et al. Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. *Forensic Sci Int*. 2010;196(1-3):93–96.
78. Mandrioli R, Mercolini L, Saracino MA, et al. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. *Curr Med Chem*. 2012;19(12):1846–1863.
79. Reis M, Lundmark J, BjörkH, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. *Ther Drug Monit*. 2002;24(4):545–553.
80. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. *Pharmacotherapy*. 1996;16(5):915–923.
81. Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. *J Clin Psychopharmacol*. 2009;29(1):39–43.
82. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. *Drug Metab Dispos*. 2003;31(9):1142–1150.
83. Lobo ED, Quinlan T, O'Brien L, et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. *Clin Pharmacokinet*. 2009;48(3):189–197.
84. Lobo ED, Lohin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. *Clin Pharmacokinet*. 2008;47(2):103–109.
85. Wang X, Abdelrahman DR, Zharikova OL, et al. Bupropion metabolism by human placenta. *Biochem Pharmacol*. 2010;79(11):1684–1690.
86. Hemauer SJ, Patrikeeva SL, Wang X, et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. *Biochem Pharmacol*. 2010;80(7):1080–1086.
87. Faucette SR, Hawke RL, Shord SS, et al. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. *Drug Metab Dispos*. 2001;29(8):1123–1129.
88. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. *Drug Metab Dispos*. 2000;28(10):1176–1183.
89. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. *Pharmacogenetics*. 2003;13(10):619–626.
90. Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. *Pharmacogenetics*. 2004;14(4):225–238.
91. Störmer E, von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. *Drug Metab Dispos*. 2000;28(10):1168–1175.
92. Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. *Clin Drug Investig*. 1998;15(1):45–55.
93. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. *Clin Pharmacokinet*. 2000;38(6):461–474.
94. Jaquenoud Sirot E, Harenberg S, Vandel P, et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. *J Clin Psychopharmacol*. 2012;32(5):622–629.
95. Borobia AM, Novalbos J, Guerra-López P, et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. *Pharmacol Res*. 2009;59(6):393–398.
96. Rotzinger S, Bourin M, Akimoto Y, et al. Metabolism of some “second”- and “fourth”-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. *Cell Mol Neurobiol*. 1999;19(4):427–442.
97. Mihara K, Yasui-Furukori N, Kondo T, et al. Relationship between plasma concentrations of trazodone and its active metabolite, *m*-chlorophenylpiperazine, and its clinical effect in depressed patients. *Ther Drug Monit*. 2002;24(4):563–566.
98. Praprotnik M, Waschgl R, König P, et al. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? *Int J Clin Pharmacol Ther*. 2004;42(2):120–124.
99. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. *Am J Psychiatry*. 1993;150(10):1541–1542.
100. Altschuler LL, Hendrick VC. Pregnancy and psychotropic medication: changes in blood levels. *J Clin Psychopharmacol*. 1996;16(1):78–80.
101. Wynn GH, Sandson N, Muniz J. *Clinical Manual of Drug Interaction: Principles for Medical Practice*. Washington, DC: American Psychiatric Publishing, Inc; 2009.
102. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. *CNS Drugs*. 2009;23(4):331–349.
103. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. *CNS Drugs*. 2011;25(4):289–298.
104. Malhi GS, Tanious M, Das P, et al. The science and practice of lithium therapy. *Aust N Z J Psychiatry*. 2012;46(3):192–211.
105. Thomsen K, Schou M. Avoidance of lithium intoxication: advice based on knowledge about the renal lithium clearance under various circumstances. *Pharmacopsychiatry*. 1999;32(3):83–86.
106. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. *J Clin Psychiatry*. 1998;59(suppl 6):57–64; discussion 65.
107. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. *CNS Drugs*. 2009;23(5):397–418.
108. Sabers A, Dam M, A-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. *Acta Neurol Scand*. 2004;109(1):9–13.
109. Ohman I, Beck O, Vitols S, et al. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. *Epilepsia*. 2008;49(6):1075–1080.
110. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. *Seizure*. 2008;17(2):199–202.
111. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. *Neurology*. 2002;59(2):251–255.
112. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. *Epilepsy Res*. 2005;65(3):185–188.
113. Fotopoulou C, Kretz R, Bauer S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. *Epilepsy Res*. 2009;85(1):60–64.
114. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and

- Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009;73(2):142–149.
115. Pennell PB, Hovinga CA. Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics. *Int Rev Neurobiol*. 2008;83:227–240.
 116. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. *Clin Pharmacokinet*. 2007;46(3):209–219.
 117. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. *Neurology*. 2004;63(3):571–573.
 118. Franco V, Mazzucchelli I, Gatti G, et al. Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. *Ther Drug Monit*. 2008;30(4):544–547.
 119. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. *Epilepsia*. 2000;41(6):709–713.
 120. Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. *J Clin Psychiatry*. 2002;63(suppl 4):3–11.
 121. De Santis M, De Luca C, Mappa I, et al. Antiepileptic drugs during pregnancy: pharmacokinetics and transplacental transfer. *Curr Pharm Biotechnol*. 2011;12(5):781–788.
 122. Bernus I, Hooper WD, Dickinson RG, et al. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. *Epilepsy Res*. 1995;21(1):65–75.
 123. Tomson T, Lindbom U, Ekqvist B, et al. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. *Epilepsia*. 1994;35(1):122–130.
 124. Battino D, Binelli S, Bossi L, et al. Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery. *Clin Pharmacokinet*. 1985;10(3):279–284.
 125. Dam M, Christiansen J, Munck O, et al. Antiepileptic drugs: metabolism in pregnancy. *Clin Pharmacokinet*. 1979;4(1):53–62.
 126. Lander CM, Eadie MJ. Plasma antiepileptic drug concentrations during pregnancy. *Epilepsia*. 1991;32(2):257–266.
 127. Gjerde IO, Strandjord RE, Ulstein M. The course of epilepsy during pregnancy: a study of 78 cases. *Acta Neurol Scand*. 1988;78(3):198–205.
 128. Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. *Folia Psychiatr Neurol Jpn*. 1985;39(1):33–41.
 129. Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. *Epilepsy Res*. 1990;5(3):223–228.
 130. Wisner KL, Leckman-Westin E, Finnerty M, et al. Valproate prescription prevalence among women of childbearing age. *Psychiatr Serv*. 2011;62(2):218–220.
 131. Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. *Acta Neurol Scand*. 1985;72(5):460–463.
 132. Levy RH, Yerby MS. Effects of pregnancy on antiepileptic drug utilization. *Epilepsia*. 1985;26(suppl 1):S52–S57.
 133. Koerner M, Yerby M, Friel P, et al. Valproic acid disposition and protein binding in pregnancy. *Ther Drug Monit*. 1989;11(3):228–230.
 134. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. *Neurology*. 1992;42(4 suppl 5):12–16.
 135. Johannessen SI. Pharmacokinetics of valproate in pregnancy: mother-fetus-newborn. *Pharm Weekbl Sci*. 1992;14(3A):114–117.
 136. Riva R, Albani F, Contin M, et al. Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid. *Ther Drug Monit*. 1984;6(1):25–30.
 137. Linden S, Rich CL. The use of lithium during pregnancy and lactation. *J Clin Psychiatry*. 1983;44(10):358–361.
 138. Ward S, Wisner KL. Collaborative management of women with bipolar disorder during pregnancy and postpartum: pharmacologic considerations. *J Midwifery Womens Health*. 2007;52(1):3–13.
 139. Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. *Am J Psychiatry*. 2005;162(11):2162–2170.
 140. Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. *Acta Neurol Scand*. 2012;126(1):e1–e4.
 141. Krishnamurthy KB. Managing epilepsy during pregnancy: assessing risk and optimizing care. *Curr Treat Options Neurol*. 2012;14(4):348–355.
 142. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. *Clin Pharmacokinet*. 2002;41(15):1247–1266.
 143. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. *Ther Drug Monit*. 2000;22(4):446–454.
 144. Mauri MC, Laini V, Cerveri G, et al. Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. *Prog Neuropsychopharmacol Biol Psychiatry*. 2002;26(3):597–601.
 145. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry*. 1987;150:782–786.
 146. Bergink V, Kooistra L, Lambregtse-van den Berg MP, et al. Validation of the Edinburgh Depression Scale during pregnancy. *J Psychosom Res*. 2011;70(4):385–389.
 147. Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. *Bipolar Disord*. 2002;4(5):323–327.
 148. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. *Br J Psychiatry*. 2008;192(5):338–343.
 149. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. *Acta Psychiatr Scand*. 2010;121(6):471–479.
 150. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. *Am J Psychiatry*. 2000;157(2):179–184.
 151. Sproule B. Lithium in bipolar disorder: can drug concentrations predict therapeutic effect? *Clin Pharmacokinet*. 2002;41(9):639–660.
 152. Schou M. Lithium treatment during pregnancy, delivery, and lactation: an update. *J Clin Psychiatry*. 1990;51(10):410–413.
 153. Galbally M, Snellen M, Walker S, et al. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. *Aust N Z J Psychiatry*. 2010;44(2):99–108.
 154. Malzacher A, Engler H, Drack G, et al. Lethargy in a newborn: lithium toxicity or lab error? *J Perinat Med*. 2003;31(4):340–342.
 155. Tanaka T, Moretti ME, Verjee ZH, et al. A pitfall of measuring lithium levels in neonates. *Ther Drug Monit*. 2008;30(6):752–754.
 156. Schou M, Amdisen A, Steenstrup OR. Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery. *Br Med J*. 1973;2(5859):137–138.
 157. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? *Clin Pharmacokinet*. 2000;38(3):191–204.
 158. Harlow BL, Vitonis AF, Sparen P, et al. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without

- prior prepregnancy or prenatal psychiatric hospitalizations. *Arch Gen Psychiatry*. 2007;64(1):42–48.
159. Heron J, Robertson Blackmore E, McGuinness M, et al. No 'latent period' in the onset of bipolar affective puerperal psychosis. *Arch Womens Ment Health*. 2007;10(2):79–81.
160. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. *J Womens Health (Larchmt)*. 2006;15(4):352–368.
161. Mawhinney E, Campbell J, Craig J, et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important? *Seizure*. 2012;21(3):215–218.
162. Semczuk-Sikora A, Czuczwar S, Semczuk A, et al. Valproic acid transfer across human placental cotyledon during dual perfusion in vitro. *Ann Agric Environ Med*. 2010;17(1):153–157.
163. Tsuru N, Maeda T, Tsuruoka M. Three cases of delivery under sodium valproate—placental transfer, milk transfer and probable teratogenicity of sodium valproate. *Jpn J Psychiatry Neurol*. 1988;42(1):89–96.
164. Sirmagul B, Atli O, Ilgin S. The effect of combination therapy on the plasma concentrations of traditional antiepileptics: a retrospective study. *Hum Exp Toxicol*. 2012;31(10):971–980.
165. Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. *Clin Ther*. 2009;31(Pt 1):1426–1453.
166. Matsui DM. Therapeutic drug monitoring in pregnancy. *Ther Drug Monit*. 2012;34(5):507–511.